293 related articles for article (PubMed ID: 37508567)
1. Targeting Soluble Guanylyl Cyclase during Ischemia and Reperfusion.
Mace EH; Kimlinger MJ; Billings FT; Lopez MG
Cells; 2023 Jul; 12(14):. PubMed ID: 37508567
[TBL] [Abstract][Full Text] [Related]
2. Soluble Guanylate Cyclase Stimulators and Activators.
Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
[TBL] [Abstract][Full Text] [Related]
3. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
[TBL] [Abstract][Full Text] [Related]
4. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
5. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
Sandner P; Stasch JP
Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
[TBL] [Abstract][Full Text] [Related]
6. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
Sandner P
Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
[TBL] [Abstract][Full Text] [Related]
7. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
8. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
9. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension.
Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920
[TBL] [Abstract][Full Text] [Related]
10. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
11. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Koress C; Swan K; Kadowitz P
Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
[TBL] [Abstract][Full Text] [Related]
12. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.
Buys ES; Zimmer DP; Chickering J; Graul R; Chien YT; Profy A; Hadcock JR; Masferrer JL; Milne GT
Nitric Oxide; 2018 Aug; 78():72-80. PubMed ID: 29859918
[TBL] [Abstract][Full Text] [Related]
14. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
15. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
Stehle D; Xu MZ; Schomber T; Hahn MG; Schweda F; Feil S; Kraehling JR; Eitner F; Patzak A; Sandner P; Feil R; Bénardeau A
Br J Pharmacol; 2022 Jun; 179(11):2476-2489. PubMed ID: 34096053
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
19. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
Priviero FB; Webb RC
J Cardiovasc Pharmacol; 2010 Sep; 56(3):229-33. PubMed ID: 20571429
[TBL] [Abstract][Full Text] [Related]
20. The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
Cordwin DJ; Berei TJ; Pogue KT
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):593-600. PubMed ID: 34487435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
